🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

On the evening of June 1st, please join Dr Neil Love, my turtleneck, and 4 other esteemed faculty for a discussion on advanced prostate cancer treatment. Now that’s “edutainment”!

The next-gen Halabi model. ctDNA content, AR enhancer gains, and other genomic factors add prognostic impact beyond clinical factors. Congrats to the Scott Dehm group for serving as the central ctDNA lab for this trial. Scott Dehm

TRIUMPH study: First trial to show that PARP inhibition can work in the absence of ADT (hormone-sparing approach) for men with germline HRR-altered mHSPC, esp. for gBRCA2! Congrats to Mark C. Markowski for leading this paradigm-shifting trial. Cathy Handy Marshall, MD MPH academic.oup.com/oncolo/advance…

Congrats Eamon Toye and Alex Chehrazi-Raffle, MD on your 2 recent papers studying BRAF alterations in PCa. Unlike other BRAF-altered cancers, PCa is characterized by Class II muts and activating fusions, including AR-regulated BRAF fusions. aacrjournals.org/clincancerres/… oncotarget.com/article/28612/…

BRCAaway: Most compelling study suggesting that combined Abi+Olap is better than sequential Abi→Olap or Olap→Abi for BRCA/ATM-altered 1st-line mCRPC. Congrats to Maha Hussain, The PCCTC, Neeraj Agarwal, MD, FASCO, Arul Chinnaiyan, Zachery Reichert, Leonidas Platanias, MD doi.org/10.1158/1078-0…

Huge congrats to Cathy Handy Marshall, MD MPH and Benjamin Teply for this paradigm-breaking study. In BCR prostate cancer, Olaparib shows profound activity (w/out ADT!) in HRRm+ pts, esp. in BRCA2+ pts (100% response rate). The PCCTC Johns Hopkins Kimmel Cancer Center @umncancer jamanetwork.com/journals/jamao…

Six genes involved in androgen production/ uptake/ conversion (APUC) distinguish ligand-driven PCa from AR-driven PCa, and have unique clinical outcomes. Congrats to Justin Hwang and his team. Nima Sharifi Charles Ryan Caris Life Sciences insight.jci.org/articles/view/…

Amphicrine prostate cancer may be a transitional state between prostate adenoCa and small cell/NEPC. Upregulation of FOXA1 and OTX2 may play a role. Congrats to Megan Ludwig for this deep multi-omic analysis. Masonic Cancer Center, University of Minnesota UMN Medicine Justin M. Drake, PhD Ali Arafa nature.com/articles/s4169…

Fascinating case report by Laura Sena on a PCa patient with heterogeneous prostatic lesions, one with MMR deficiency and the other with BRCA2 loss, both of which led to metastatic outgrowths at different time points and selection pressures.

Congrats Ali Arafa for developing a new method for robust plasma exosome proteomics capable of detecting and quantifying >5000 proteins incl. PSMA, B7H3, TROP2 and STEAP1. A new blood-based biomarker is born! University of Minnesota mdpi.com/2072-6694/16/2…

The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Different FOXA1 classes have different biologic behaviors, clinical outcomes & racial clustering, esp. Class 1B and 2. @UMNcancer Scott Dehm aacrjournals.org/clincancerres/…

Congratulations Cathy Handy Marshall, MD MPH and thanks to @mrinalpatnaik for mentoring us

Thank you Neeraj Agarwal, MD, FASCO for conducting such a masterful interview and for recognizing the importance of this work

Congrats to John Lozada (MD/PhD student) for deeply characterizing DLL3 expression in neuroendocrine cancers across 29 tumor sites. Caris Life Sciences Masonic Cancer Center, University of Minnesota University of Minnesota Misha Beltran aacrjournals.org/cancerrescommu…

Largest study of BRCA-associated cancers (24,309) shows that somatic tumor landscape is influenced by germline HRR muts: gBRCA1-altered cancers are enriched in somatic TP53 muts; gATM-altered cancers are depleted in TP53 mut. Congrats Ali Arafa @umncancer aacrjournals.org/clincancerres/…

Congratulations to Cathy Marshall on her two papers (in the same week!) exploring CH in solid tumors. This is an important and emerging field. Cathy Handy Marshall, MD MPH Tempus academic.oup.com/oncolo/article… mdpi-res.com/d_attachment/c…

Congratulations Ali Arafa on developing the first prognostic blood-based PROTEOMIC biomarker for 177Lu-PSMA-617 efficacy, presented at ASCO ‘25. Masonic Cancer Center, University of Minnesota University of Minnesota meetings.asco.org/abstracts-pres…

Just in Clinical Cancer Research 👉Congrats Chadi Hage Chehade Umang Swami & GU Cancer Research Program @HuntsmanCancer team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 Flatiron Health Foundation Medicine Ryon Graf, PhD 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i OncoAlert UroToday.com

Congrats Chadi Hage Chehade for this impactful study. You are a superstar ⭐️

A novel west-African germline founder mutation in HOXB13 (p.X285Kext) increases risk of high-grade prostate cancer but also enhances sensitivity to hormonal therapy. Congrats to PCF-funded Mayuko Kanayama 👏 Neeraj Agarwal, MD, FASCO Prostate Cancer Foundation UroToday.com Ed Esplin, MD, PhD nature.com/articles/s4139…